ABSTRACT
Introduction Earlier food surveys showed deficient dietary potassium in rheumatoid arthritis (RA).
Objective To evaluate an adjunct role of oral potassium to reduce joint pain in RA
Methods 172 consenting and eligible symptomatic patients (median duration 6.5 years) on standard care were randomized into an assessor blind, parallel efficacy, controlled, multi-arm single center study (80% power) of 16 weeks duration-Arm A (potassium rich vegetarian diet), Arm B (Arm A plus novel potassium food supplement) and Arm C (Control, regular diet). Standard efficacy (American College of Rheumatology) and safety, and diet intake (three-day recall) were assessed at monthly intervals (protocol). Standard statistical tests were used; significant p <0.05, two sided). Study arms were well matched at baseline and RA medication remained fairly stable. Patients in Arm A and B met the pre-set target for increased potassium intake (diet analysis, India standards) and remained normokalemic. Diet remained unchanged in Arm C.
Results 155 patients (90.1%) completed and several showed improvement (best in Arm B). Potassium intervention was safe and well tolerated. Adverse events were mild; none caused patient withdrawal. On comparison, the mean change in pain visual analogue scale (−2.23, 95% confidence interval −2.99 to −1.48) at week 16 (primary efficacy) from baseline in Arm B was significantly superior as per protocol analysis. A high daily potassium intake (5-7.5 gm, Arm B) was significantly associated with low pain (study completion); Odds Ratio 2.5, Univariate Analysis and Likelihood Ratio 2.9, Logistic Regression. Compliance (intervention), diet record and analysis, RA medication and absence of placebo were potential confounders.
Conclusion High oral potassium intake based on a suitable diet and food supplement, reduced joint pain and improved RA. It was a safe adjunct and ought to be considered for standard care in RA. Further validation studies are required.
Trial Registration Clinical Trial Registry of India-CTRI/2022/03/040726
What is already known on the topic?
Potassium is a vital micronutrient in health, but little is known about its role in RA.
Patients suffering from symptomatic RA may consumed potassium deficient diet
What this study adds?
Increased potassium intake based on a suitable vegetarian diet and a novel food supplement may joint pain and improve RA
High oral potassium intake was found safe and well tolerated
How this study might affect research, practise or policy/
A high potassium intake based on vegetarian diet and food is a useful adjunct to manage difficult symptomatic RA in clinical practise.
The current recommendations/guidelines on potassium intake should be revised
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
CTRI/2022/03/040726
Funding Statement
This study did not receive any funding from any external or commercial source. Non-commercial investigator initiated study and partly funded by Arthritis Research Care Foundation - Center for Rheumatic Diseases, Pune, India.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee, Arthritis Research Care Foundation Center for Rheumatic Diseases, Pune, India. The approval letter dated 04 Feb 2014 is enclosed as a supporting document
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The paper is more concise with elaborate description of methods and more data/Tables added-background RA mediation (Table 6) and increased potassium intake in the study (Table 2). Data on blood pressure response added. The discussion has a more elaborate description of strengths and limitations. Speculation on mechanism of action is added. The supplement file is revised to make it concise and for better understanding. The data on primary and secondary efficacy measures and conclusion remains unchanged.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
